Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Staber Philipp |

Presentations at scientific and public conferences

Kazianka, L; Pemovska, T; Rohrbeck, J; Kornauth, C; Pichler, A; Agreiter, C; Hauptmann, L; Lubowitzki, S; Prochazka, K; Neumeister, P; Schmitt, C; Greil, R; Willenbacher, W; Wolf, D; Simonitsch-Klupp, ; Staber, P Precision medicine in clinical routine: feasibility results from the multicentric prospective randomized controlled EXALT-2 Study
ONCOL RES TREAT. 2023; 46: 293-294. [Poster]
Web of Science

 

Kazianka, L; Pemovska, T; Rohrbeck, J; Kornauth, C; Pichler, A; Agreiter, C; Lubowitzki, S; Prochazka, K; Neumeister, P; Schmitt, C; Greil, R; Willenbacher, W; Wolf, D; Jaeger, U; Simonitsch-Klupp, I; Staber, PB Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial
BLOOD. 2023; 142: Doi: 10.1182/blood-2023-189856
Web of Science FullText FullText_MUG

 

Kenner, L; Laimer, D; Dolznig, H; Vesely, P; Kollmann, K; Schiefer, AII; Sexl, V; Staber, PB; Hoefler, G; Penninger, J; Inghirami, G; Ulrich, J New and Highly Efficient Therapy for Treatment NPM-ALK Associated Lymphomas
BLOOD. 2011; 118(21): 721-721.
Web of Science

 

Langner, S; Staber, P; Linkesch, W; Strunk, D Long-term follow-up of minimal chronic graft-versus-host disease after reduced-intensity conditioning with pre-transplant low dose anti-thymocyte globulin in allogeneic stem cell transplantation
BONE MARROW TRANSPLANT. 2010; 45: S145-S145. - 36th Annual Meeting of the European Group for Blood and Marrow Transplantation; MAR 21-24, 2010; Vienna, AUSTRIA. [Poster]
Web of Science

 

Fuchs, C; Vesely, P; Bambach, I; Schauer, S; Linkesch, W; Stemberg, DW; Hoefler, G; Staber, PB Identification of critical phosporylation sites within NPM-ALK that regulate JUNB mRNA translation
BLOOD. 2007; 110(11):1044A-1045A.-49 th Annual Meeting of the American Society of Hematology; NOV 8-11, 2007; Atlanta, Georgia, USA. [Poster]
Web of Science

 

Laimer, D; Vesely, P; Staber, P; Pflegerl, P; Brandes, R; Schlederer, M; Hoefler, G; Kenner, L Role of junb in ALCL lymphoma development
HAEMATOL-HEMATOL J. 2007; 92: 344-344.Vienna. [Poster]
Web of Science

 

Langner, S; Staber, P; Schub, N; Gramatzki, M; Grothe, W; Behre, G; Rabitsch, W; Linkesch, W; Neumeister, P Palifermin in unrelated donor transplant recipients
HAEMATOL-HEMATOL J. 2007; 92: 172-173. [Poster]
Web of Science

 

Langner, S; Staber, P; Strunk, D; Linkesch, W Decreased chronic GVHD rate after reduced intensity conditioning with low dose ATG in allogeneic hematopoietic SCT
HAEMATOL-HEMATOL J. 2007; 92: 220-220.-12th Congress of the European Hematology Association; JUN 7-10, 2007; Vienna, AUSTRIA. [Poster]
Web of Science

 

Staber, P; Vesely, P; Fuchs, C; Bambach, I; Schauer, S; Bergler, H; Sternberg, D; Hoefler, G The oncoprotein NPM-ALK induces translation of AP-1 factors via mTOR signalling
HAEMATOL-HEMATOL J. 2007; 92: 344-344.Vienna. [Oral Communication]
Web of Science

 

Staber, PB; Vesely, P; Fuchs, C; Schauer, S; Sternberg, DW; Hoefler, G NPM-ALK induces JUNB and converts its role from a tumor suppressor to an oncogene
FEBS J. 2007; 274: 150-150. [Poster]
Web of Science

 

Staber PB; Vesely P; Sternberg W; Ott, RG; Kadin, ME; Linkesch, W; Schauer, S; Sexl, V; Kenner, L; Hoefler, G NPM-ALK fusion tyrosine kinase of anaplastic large cell lymphoma promotes neoplasia by inducing JunB via ERK1/2 and mTOR signalling
Wiener Medizinische Wochenschrift2007; 157(121):5-5.-Frühjahrestagung 2007 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 12-14, 2007; Wien. [Oral Communication]

 

Vesely, P; Staber, P; Fuchs, C; Bambach, I; Schauer, S; Sternberg, D; Kenner, L; Hoefler, G Expression of NPM-ALK leads to oncogenic effects of JunB
HAEMATOL-HEMATOL J. 2007; 92: 107-107.Vienna. [Oral Communication]
Web of Science

 

Vesely, P; Staber, PB; Fuchs, C; Schauer, S; Bergler, H; Sternberg, DW; Hoefler, G Translational control of JUNB via the fusion tyrosine kinase NPM-ALK in ALC(L) lymphoma
FEBS J. 2007; 274: 150-150. [Poster]
Web of Science

 

Deutsch, A; Aigelreiter, A; Staber, P; Beham-Schmid, C; Beha, A; Frühwirth, M;Linkesch, W; Neumeister, P Extranodal marginal zone B-cell lymphoma of MALT type are targeted by aberrant somatic hypermutation.
Onkologie2006; 29(S3)VIII+256(2006): -DGHO ; NOV 4-8, 2006; Leipzig, Germany. [Oral Communication]

 

Fruehwirth, M; Deutsch, AJA; Staber, PB; Aigelsreiter, A; Linkesch, W; Beham-Schimid, C; Neumeister, P Aberrant somatic hypermutation of follicular lymphoma transformed to diffuse large B-cell lymphoma.
BLOOD. 2006; 108(11): 683A-683A. Doi: 10.1182/blood.V108.11.2413.2413 [Poster]
Web of Science FullText FullText_MUG

 

Langner, S; Staber, P; Radspieler, G; Triebl-Roth, K; Urban, C; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Neumeister, P Palifermin reduces oral mucositis and enhances the recovery of intestinal mucosa measured by citrulline serum levels in allogeneic and autologous stem cell transplant recipients
BONE MARROW TRANSPLANT. 37: S73-S74.-32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group; MAR 19-22, 2006; Hamburg, GERMANY. [Poster]
Web of Science

 

Langner, S; Staber, PB; Strunk, D; Linkesch, W Pretransplant low dose anti-thymocyte globulin showed a decreased chronic graft versus host disease rate after reduced intensity conditioning in allogeneic stem cell transplantation
European Surgery. 38(S211):7-7.-Austrian Society of Transplantation, Transfusion and Genetics; OCT 18-21, 2006; Hof - Salzburg, AUSTRIA. [Oral Communication]

 

Langner, S; Staber, PB; Strunk, D; Linkesch, W Pre-transplant low dose anti-thymocyte glubulin showed a decreased cGvHD rate after reduced intensity conditioning in allogeneic stem cell tranplantation
Onkologie. 2006; 29(S3):119-119.-German, Austrian and Swiss Societies of Hematology and Oncology; NOV 4-8, 2006; Leipzig, GERMANY. [Poster]

 

Langner, S; Staber, PB; Zebisch, A; Triebl-Roth, K; Urban, C; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Neumeister, P Reduced oral mucositis and enhanced intestinal mucosal recovery measured by citrulline serum levels in allogeneic and autologous stem cell transplant recipients treated with palifermin
Onkologie. 29(S3):125-126.-German, Austrian and Swiss Societies of Hematology and Oncology; NOV 4-8, 2006; Leipzig, GERMANY. [Poster]

 

Langner, S; Staber, PB; Zebisch, A; Zinke-Cerwenka, W; Sill, H; Linkesch, W; Greinix, H; Kalhs, P; Rabitsch, W; Neumeister, P Adding palifermin in allogeneic and autologous stem cell transplantation resulted in reduced oral mucositis and enhanced intestinal mucosal recovery measured by citrulline serum levels.
BLOOD. 2006; 108(11): 404B-404B. Doi: 10.1182/blood.V108.11.5251.5251 [Poster]
Web of Science FullText FullText_MUG

 

Staber, PB; Vesely, P; Ott, R; Haq, N; Linkesch, W; Schauer, S; Hrzenjak, A; Kenner, L; Dirks, W; Kadin, ME; Sternberg, DW; Hoefler, G NPM-ALK fusion tyrosine kinase of anaplastic large cell lymphoma exerts its transforming potential by increasing translation of JUNB through mTOR and S6K1.
BLOOD. 2006; 108(11): 414A-415A. Doi: 10.1182/blood.V108.11.1428.1428 [Poster]
Web of Science FullText FullText_MUG

 

Vesely, P; Staber, PB; Ott, R; Pinent, M; Linkesch, W; Schauer, S; Hrzenjak, A; Kadin, ME; Sternberg, DW; Hoefler, G NPM-ALK converts JUNB from a tumor suppressor to an oncogene.
BLOOD. 2006; 108(11): 419A-420A. Doi: 10.1182/blood.V108.11.1448.1448 [Poster]
Web of Science FullText FullText_MUG

 

Macher, S; Schallmoser, K; Rosskopf, K; Posch, U; Neumeister, P; Staber, PB; Panzer, S; Lanzer, G Severe immune thrombocytopenia due to HPA-1a host-derived antibodies after non-myeloablative allogeneic hematopoietic stem cell transplantation for multiple myeloma
Vox sanguinis. 2005; 89(1):157--No Conference; None; None.

 

Macher, S; Schallmoser, K; Staber, P; Neumeister, P; Rosskopf, K; Posch, U; Panzer, S; Lanzer, G Severe immune thrombocytopenia due to HPA-1 a host-derived antibodies after non-myeloablative allogeneic hematopoetic stem cell transplantation for multiple myeloma
TRANSFUSION 2005 45: 114A-114A.
Web of Science

 

Macher, S; Schallmoser, K; Staber, PB; Neumeister, P; Rosskopf, K; Posch, U; Panzer, S; Lanzer, G Severe immune thrombocytopenia due to HPA-1a host-derived antibodies after non-myeloablative allogeneic hematopoietic stem cell transplantation for multiple myeloma
Wiener Medizinische Wochenschrift2005; 117: -9. Frühjahrstagung 2005 der Österreichischen Gesellschaft für Hämatologie und Onkologie; APR 28-30, 2005; Graz, AUSTRIA. [Poster]

 

Macher S, Schallmoser K, Staber PB, Neumeister P, Rosskopf K, Posch U, Panzer S, Lanzer G Severe immune thrombocytopenia due to HPA-1a host-derived antibodies after non-myeloablative allogeneic hematopoietic stem cell transplantation for multiple myeloma
Haematologica/The Hematology Journal2005; 90(S2):274--10th Meeting of the European Hematology Association (EHA); JUN 2-5, 2005; Stockholm, Sweden. [Poster]

 

Neumeister, P; Holub, R; Staber, PB; Linkesch, W Pegfilgrastim shows safety and efficacy similar to filgrastim in patients undergoing autologous stem cell transplantation for hematological malignancies.
BLOOD 2004 104: 327A-327A. Doi: 10.1182/blood.V104.11.1156.1156
Web of Science FullText FullText_MUG

 

Staber, PB; Linkesch, W; Schauer, S; Moser, G; Kadin, ME; Dirks, W; Hoefler, G Genes regulated by NPM-ALK fusion kinase play a key role in the activation of AP-1 transcription factors.
BLOOD 2004 104: 74A-74A. Doi: 10.1182/blood.V104.11.245.245
Web of Science FullText FullText_MUG

 

Zebisch, A; Staber, PB; Fischereder, K; Bodner, C; Hiden, K; Linkesch, W; Auner, HW; Emberger, W; Windpassinger, C; Schimek, MG; Hoefler, G; Troppmair, J; Sill, H Two novel activating germline mutations of the C-RAF proto-oncogene predisposing to solid tbmors and therapy-related acute myeloid leukemia.
BLOOD 2004 104: 920A-920A. Doi: 10.1182/blood.V104.11.3370.3370
Web of Science FullText FullText_MUG

 

Zinke-Cerwenka, W; Eibl, M; Sill, H; Hofler, G; Staber, P; Linkesch, W Continuous molecular response after discontinuation of imatinib mesylate following relapse after non-myeloablative allogeneic stem cell transplantation for CML
BONE MARROW TRANSPLANT 2004 33: S348-S348.
Web of Science

 

Höfler, G; Staber, PB; Beham-Schmid, C; Guelly, C; Schauer, S; Linkesch, W Increased proliferation rate and activation of the B-RAF/MEK/Erk pathway at relapse of acute myeloid leukemia
MODERN PATHOL 2003 16: 235A-236A.
Web of Science

 

Höfler, G; Staber, PB; Beham-Schmid, C; Guelly, C; Schauer, S; Linkesch, W Increased proliferation rate and activation of the B-RAF/MEK/erk pathway at relapse of acute myeloid leukemia
LAB INVEST 2003 83: 235A-236A.
Web of Science

 

Staber, PB; Neumeister, P; Duerkop, H; Schauer, S; Linkesch, W; Hoefler, G CD30 induced cell death in anaplastic large cell lymphoma involves perforin/granzyme cell death pathway and the caspase dependent death receptors TNFR-1 and FAS/APO-1.
BLOOD 2003 102: 885A-885A.
Web of Science

 

Bernhart, E; Noehammer, C; Staber, P; Schaffer, P; Höfler, G; Koidl, B A mouse model of metabolic cardiomyopathy shows alterations of ventricular electrophysiology
BIOPHYS J 2002 82: 477-477.
Web of Science

 

Staber, PB; Hoefler, G; Beham-Schmid, C; Guelly, C; Schauer, S; Linkesch, W Increased proliferation rate in acute myeloid leukemia blasts at relapse due to activation of the B-Raf/MEK/Erk pathway.
BLOOD 2002 100: 330A-330A.
Web of Science

 

↑ Top of page / Navigation

© Med Uni Graz • Imprint